Gland Pharma Ltd. AI Stock Analysis
Want to see IN:GLAND full AI Analyst Report?
Gland Pharma Ltd. (GLAND) AI Stock Analysis
Gland Pharma Ltd.
(NSE:GLAND)
The score is driven primarily by solid financial fundamentals—especially a very conservative balance sheet and improving cash flow—tempered by margin volatility. Technically, the stock has strong upward momentum but is overbought, raising near-term risk. Valuation is the main drag, with a high P/E and low dividend yield requiring continued strong execution to justify.
Gland Pharma Ltd. (GLAND) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 543.93B
- Dividend Yield
- 0.61%
- Average Volume (3M)
- 259.44K
- Price to Earnings (P/E)
- 43.5
- Beta (1Y)
- 0.71
- Revenue Growth
- 21.90%
- EPS Growth
- 56.28%
- Country
- India
- Employees
- 4,332
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Gland Pharma Ltd. Business Overview & Revenue Model
Company Description
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical i...
How the Company Makes Money
Gland Pharma makes money primarily by manufacturing and supplying sterile injectable pharmaceutical products to other pharmaceutical companies and healthcare product marketers. Its core revenue streams typically include: (1) Contract development and...
Gland Pharma Ltd. Financial Statement Overview
Summary
Strong balance sheet (very low leverage; steady positive ROE) and improving cash generation support the score. Offsetting this, profitability has been volatile, with a sharp gross margin drop in FY2026 versus FY2024–FY2025, making margin stability and earnings quality key watch items.
Income Statement
62PositiveBalance Sheet
88Very PositiveCash Flow
70Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.25B | 64.31B | 56.17B | 56.65B | 36.25B | 44.01B |
| Gross Profit | 20.67B | 19.32B | 31.54B | 31.11B | 17.65B | 21.51B |
| EBITDA | 19.86B | 19.22B | 12.50B | 13.16B | 10.31B | 15.10B |
| Net Income | 11.29B | 10.27B | 6.99B | 7.72B | 7.81B | 12.12B |
Balance Sheet | ||||||
| Total Assets | 0 | 125.11B | 112.25B | 106.61B | 87.78B | 78.34B |
| Cash, Cash Equivalents and Short-Term Investments | 33.59B | 34.33B | 29.52B | 19.39B | 37.63B | 32.43B |
| Total Debt | 0 | 2.84B | 3.14B | 3.72B | 44.53M | 47.43M |
| Total Liabilities | -103.58B | 21.53B | 20.74B | 19.37B | 8.19B | 6.76B |
| Stockholders Equity | 103.58B | 103.58B | 91.51B | 87.24B | 79.59B | 71.58B |
Cash Flow | ||||||
| Free Cash Flow | 3.99B | 7.41B | 5.30B | 6.07B | 1.41B | 2.69B |
| Operating Cash Flow | 5.93B | 12.31B | 9.15B | 9.97B | 3.64B | 7.91B |
| Investing Cash Flow | -923.82M | -945.34M | 17.05B | -17.57B | 12.08B | -10.03B |
| Financing Cash Flow | -3.79B | -3.85B | -4.33B | -7.99B | 149.19M | 348.98M |
Gland Pharma Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAND, the sentiment is Positive. The current price of 3260.70 is above the 20-day moving average (MA) of 3058.27, above the 50-day MA of 2988.93, and above the 200-day MA of 2314.35, indicating a bullish trend. The MACD of 73.26 indicates Negative momentum. The RSI at 66.20 is Neutral, neither overbought nor oversold. The STOCH value of 80.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLAND.
Gland Pharma Ltd. Peers Comparison
Overall Rating
IN:ABBOTINDIA81Outperform
IN:CIPLA79Outperform
IN:MARKSANS78Outperform
IN:GLAXO68Neutral
IN:PFIZER67Neutral- IN:GLAND65Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:ABBOTINDIA | 81Outperform | INR 566.26B | 33.57 | ― | 1.97% | 7.21% | 9.54% |
| IN:CIPLA | 79Outperform | INR 1.14T | 39.58 | ― | 2.05% | -0.74% | -46.77% |
| IN:MARKSANS | 78Outperform | INR 139.85B | 24.80 | ― | 0.29% | 24.20% | 59.18% |
| IN:GLAXO | 68Neutral | INR 459.23B | 40.30 | ― | 2.09% | 12.12% | 20.03% |
| IN:PFIZER | 67Neutral | INR 179.31B | 20.73 | ― | 1.93% | 11.75% | 2.39% |
| IN:GLAND | 65Neutral | INR 544.76B | 43.53 | ― | 0.61% | 21.90% | 56.28% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:GLAND | Gland Pharma Ltd. | 3260.70 | 1447.42 | 79.82% | |
| IN:ABBOTINDIA | Abbott India Limited | 26100.20 | -2779.85 | -9.63% | |
| IN:CIPLA | Cipla Ltd | 1417.00 | -94.61 | -6.26% | |
| IN:GLAXO | GlaxoSmithKline Pharmaceuticals Limited | 2726.40 | 294.62 | 12.12% | |
| IN:MARKSANS | Marksans Pharma Limited | 306.45 | 118.67 | 63.19% | |
| IN:PFIZER | PFIZER LIMITED | 3893.40 | -1073.18 | -21.61% |
Gland Pharma Ltd. Corporate Events
Gland Pharma Appoints Xiao Le as Chief Investment Officer
Gland Pharma, a pharmaceutical company with international operations, has appointed Mr. Xiao Le as Chief Investment Officer of its wholly owned Singapore subsidiary, effective November 9, 2026. He will report to the subsidiary’s chief executive offic...
Gland Pharma Pays Fines for Technical Board Appointment Lapse, Tightens Compliance Controls
Gland Pharma has disclosed that Indian stock exchanges levied fines for a technical non-compliance related to appointing an independent non-executive director over the age of 75, pending shareholder approval. The breach spanned 34 days, covering the...
Gland Pharma Grants Over 590,000 ESOPs Under 2025 Scheme
Gland Pharma Ltd. has approved a fresh grant of 590,249 employee stock options to 124 employees under its Employee Stock Option Scheme 2025, as resolved by the ESOP Compensation Committee on September 13, 2026. The options are split between grants at...
Gland Pharma Boosts Capital with ESOP Share Allotment, Winds Up 2019 Plan
Gland Pharma Limited has increased its issued, subscribed and paid-up share capital to Rs. 165,010,854 following the allotment of 44,193 equity shares of face value Re.1 each to employees under its ESOP 2019 and ESOP 2025 schemes. The shares were all...
Gland Pharma Moves to Directly Own U.S. Subsidiary in Group Restructuring
Gland Pharma Limited has approved a corporate restructuring move to acquire 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd., both currently wholly owned subsidiaries. Following completion of the tra...
Gland Pharma Streamlines Structure With Direct Takeover of U.S. Subsidiary
Gland Pharma Ltd. has approved the acquisition of 100% equity in Gland Pharma USA Inc. from its wholly owned subsidiary Gland Pharma International Pte. Ltd., converting the U.S. unit into a direct wholly owned subsidiary. The related-party transactio...
Gland Pharma Highlights Manufacturing Strength and Compliance at 48th AGM
Gland Pharma Limited held its 48th Annual General Meeting on August 25, 2026 via video conferencing and other audio-visual means, ensuring shareholder participation and voting in line with Indian securities regulations. The Executive Chairman, Sriniv...
Gland Pharma Schedules Analyst and Institutional Investor Meetings for Late August
Gland Pharma Limited has notified stock exchanges about its upcoming analyst and institutional investor interactions scheduled for late August 2026. The company plans one-on-one meetings with Nomura on August 26 and a separate interaction with HDFC M...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026